"What" Series

What is Bioavailability?

29 March 2024
2 min read

Bioavailability refers to the extent and rate at which the active ingredient of a drug or nutrient is absorbed into the circulation and becomes available at the site of action within the body. It is a crucial concept in pharmacology and nutrition, as it determines the effectiveness of a drug or the utilization of a nutrient.

Key points about bioavailability include:

·Absorption: The process by which a drug or nutrient enters the bloodstream from the site of administration, such as the gastrointestinal tract.

·Distribution: The movement of the substance throughout the body, including crossing membranes and reaching target tissues or organs.

·Metabolism: The chemical transformation of the substance within the body, which can alter its activity and may involve enzymes in the liver or other tissues.

·Excretion: The elimination of the substance or its metabolites from the body, typically through urine or feces.

·Factors Affecting Bioavailability: Various factors can influence bioavailability, including the formulation of the drug, the route of administration, food interactions, and individual differences in metabolism and absorption.

·Percentage: Bioavailability is often expressed as a percentage, with 100% indicating that the entire administered dose is absorbed into the bloodstream.

·Clinical Relevance: High bioavailability is desirable as it means more of the drug or nutrient is available to exert its intended effect. Low bioavailability may require higher doses or different formulations to achieve the therapeutic effect.

·Comparative Studies: Bioavailability studies are essential when comparing different formulations or brands of the same drug to ensure they have similar therapeutic effects.

Understanding bioavailability is critical for the development of new drugs, as it helps in determining the appropriate dosing and formulation to achieve the desired therapeutic outcome. It is also important for doctors when prescribing medications to ensure that the drug will be effective for the patient.

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Apogee Therapeutics Begins Phase 1 Trial of APG808 for COPD and Inflammation
Latest Hotspot
3 min read
Apogee Therapeutics Begins Phase 1 Trial of APG808 for COPD and Inflammation
29 March 2024
Apogee Therapeutics has initiated dosing of initial volunteers in a Phase 1 study of their new extended-duration IL-4Rα antibody, APG808, aimed at managing Chronic Obstructive Pulmonary Disease (COPD) and various inflammatory conditions.
Read →
User-friendly Guide to Find Valsartan on Synapse
Drug Insights
2 min read
User-friendly Guide to Find Valsartan on Synapse
29 March 2024
Valsartan, a diminutive molecular compound, falls within the pharmacological group of angiotensin receptor blockers (ARBs).
Read →
Regeneron Announces Progress on Licensing Submission for Cancer Drug Odronextamab
Latest Hotspot
3 min read
Regeneron Announces Progress on Licensing Submission for Cancer Drug Odronextamab
29 March 2024
Regeneron Pharmaceuticals, Inc. has declared the receipt of Complete Response Letters from the U.S. Food and Drug Administration concerning their submitted Biologics License Application for the drug odronextamab.
Read →
What is Preclinical Research?
"What" Series
2 min read
What is Preclinical Research?
29 March 2024
Preclinical research refers to the scientific studies conducted on potential drugs or medical devices before they are tested in humans.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.